April 4, 2024- Mayo Clinic scientists have developed an immunotherapy strategy that potentially lays the groundwork for treating a spectrum of autoimmune diseases.
The new technique, detailed in a preclinical study published in Nature Biomedical Engineering, involves combining chimeric antigen receptors (CAR) with mesenchymal stromal cells (MSC), resulting in engineered stem cells known as CAR-MSCs.
Engineering mesenchymal stromal cells with chimeric antigen receptors shows potential in enhancing their ability to target specific cells or markers and improve their therapeutic impact.